02 · Clinical Findings
Three years of tirzepatide data sharpen the prediabetes question
These shots began life as diabetes medicine, and this is the longest look yet at whether they can keep the condition from arriving in the first place.
In a company-announced three-year study of more than 1,000 adults with obesity or overweight and prediabetes, tirzepatide was associated with a 94% lower relative risk of progressing to type 2 diabetes than placebo while treatment continued. Participants also lost substantially more weight than the placebo group.
The result matters because prediabetes is common in the United States and preventing progression could change the burden of diabetes. Relative-risk figures are not a guarantee for an individual, and the study does not establish that the medicine permanently prevents the disease.
After participants stopped treatment, weight began to return and the reduction in diabetes progression was smaller after 17 weeks. Longer independent follow-up and absolute-risk data are needed to understand durability and who benefits most.
DisclaimerEducational news and research awareness content. Not medical advice.Read full disclaimer ▾
This page shares third-party news coverage, official research listings, and public clinical updates for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.
Related context
How this story connects across the peptide landscape.
Combining two diabetes drug classes is not automatically a bigger clinical benefit
At the highest dose, retatrutide cut 21% of body weight in people with type 2 diabetes
Tirzepatide kept nearly 99% of prediabetes patients diabetes-free over three years
Continue reading · Clinical FindingsPeptide News / Clinical FindingsTirzepatide cut progression to type 2 diabetes by 94% over three yearsFierce Pharma · Aug 20, 2024 · scroll to read